{"disease":{"id":"pancreatic-neuroendocrine-tumor","name":"Pancreatic Neuroendocrine Tumor","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"everolimus","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"streptozocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanosar","generic_name":"STREPTOZOCIN","company_name":"Teva","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"sunitinib-malate","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunitinib Malate","generic_name":"sunitinib-malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":80,"revenue":null,"mechanism":"Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET."},{"drug_id":"afinitor","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sutent","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"Sunitinib Malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET","drug_class":"Small molecule kinase inhibitor","quality_score":67,"revenue":null,"mechanism":"Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression."},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumors (pNET)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"streptozotocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Streptozotocin","company_name":"Hoffmann-La Roche","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04282083","title":"Protocol ITANET - Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Italian Association Neuroendocrine Tumors","has_results":false},{"nct_id":"NCT06041009","title":"Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations","phase":"","overall_status":"RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT07439757","title":"AI-Powered Precision Decision-Making for Pancreatic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT05847855","title":"Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04074135","title":"Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02630654","title":"Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs","phase":"","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04986085","title":"Nutrition in Gastroenteropancreatic Neuroendocrine Tumor","phase":"","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":322,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT06155318","title":"68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT03375320","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":298,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05636618","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Perspective Therapeutics","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07165886","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":243,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT06784752","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06167421","title":"Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06024343","title":"Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction","phase":"NA","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03972488","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":true},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07273409","title":"Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05171517","title":"Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06557408","title":"Pancreatic Fistula After Minimally Invasive Enucleation","phase":"","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT04727723","title":"Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":164,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07274657","title":"Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"GCS Ramsay Santé pour l'Enseignement et la Recherche","has_results":false},{"nct_id":"NCT01229943","title":"Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02264665","title":"OPALINE : A Study Of Morbidity And Mortality At 2 Years","phase":"","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05040360","title":"Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":141,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05476978","title":"Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT01525550","title":"A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02948946","title":"Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT02282059","title":"The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02730104","title":"Community-based Neuroendocrine Tumor (NET) Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06158516","title":"A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06406387","title":"ATRX/DAXX in EUS-FNB Specimens of Pan-NETs","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Integrata Verona","has_results":false},{"nct_id":"NCT07328607","title":"Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT02159989","title":"Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06256705","title":"Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04505553","title":"Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03967951","title":"CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Francesco De Cobelli","has_results":false},{"nct_id":"NCT04476082","title":"Nutrition in Gastrointestinal Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"University Medicine Greifswald","has_results":false},{"nct_id":"NCT06091748","title":"Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT02842749","title":"Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03457844","title":"A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}